BeOne Medicines Establishes Global HQ in Basel

In a significant move for the global pharmaceutical industry, BeOne Medicines (formerly known as BeiGene) has announced the relocation of its legal headquarters from the Cayman Islands to Basel, Switzerland. This strategic decision positions the company alongside pharmaceutical giants Roche and Novartis in one of Europe's most prestigious life sciences hubs. The relocation comes with a corporate rebranding, marking a new chapter in the company's evolution and strengthening Switzerland's position as a global biotechnology center.

Founded in 2010, BeOne Medicines has established itself as a significant player in the oncology sector. The company, which maintains operational centers in Cambridge (US) and Beijing, has grown to employ nearly 11,000 people worldwide. Their Basel journey began modestly in 2018 with just three employees, but has since expanded to a substantial workforce of 265 professionals. This growth trajectory reflects the company's commitment to research and development in blood cancer and solid tumor treatments, positioning Basel as a crucial center for their European operations.

The establishment of BeOne Medicines' global headquarters in Basel significantly enhances the city's reputation as a leading European life sciences cluster. Basel's Director of Economic Affairs, Kaspar Sutter, welcomed the move, stating, 'I am delighted that we have succeeded in attracting BeOne Medicines, an innovative global oncology company, to Basel.' This relocation not only strengthens Basel's position as a premier biotech hub but also creates new opportunities for scientific collaboration and economic growth in the region.

BeOne Medicines' relocation to Basel signals ambitious plans for future growth and expansion. The company's focus remains on advancing cancer research, particularly in blood cancers and solid tumors. With its strategic position in Switzerland's pharmaceutical hub, BeOne Medicines is well-positioned to leverage local expertise, research facilities, and talent pool. The move is expected to facilitate closer collaboration with European research institutions and accelerate the development of innovative cancer therapies.